• PYC has three investigational drug candidates in clinical development with a fourth expected to enter human trials in H1 2027
• Highlights include establishing safety/tolerability of PKD drug candidate, progression of ADOA drug candidate to global repeat dose study, and presentation of longer-term RP11 data
• PYC continues to progress all four pipeline programs towards important human safety and efficacy data read-outs in the coming 24 months

PYC Therapeutics Limited (ASX:PYC) is a precision medicine company creating life-changing RNA therapeutics for patients with severe unmet medical needs. The company has a pipeline of four first-in-class drug candidates, three of which have advanced into human trials. In Q4 2025, PYC made significant progress across its pipeline. In the polycystic kidney disease (PKD) program, the company established the safety and tolerability profile of its drug candidate in healthy volunteers, enabling progression to Part B of the combined Phase 1a/1b study in patients. In the autosomal dominant optic atrophy (ADOA) program, PYC progressed into a global repeat dose study in patients, directed towards establishing clinical 'proof of concept' for its most advanced drug candidate in this indication. For the retinitis pigmentosa type 11 (RP11) program, PYC presented longer-term data demonstrating sustained improvement in the vision of RP11 patients who have received the company's drug candidate. In the Phelan-McDermid Syndrome (PMS) program, PYC presented results of successful Non-Human Primate studies that complement earlier data generated in PMS patient-derived brain cells. PYC continues to progress all four pipeline programs towards important human safety and efficacy data read-outs in the coming 24 months, subject to the risks and uncertainties outlined in the company's previous disclosures.

As of 31 December 2025, the Company had $121 million of cash on hand with an estimated additional $20 million expected to be received in Q1 2026 attributable to the R&D rebate applicable to FY25.